233 related articles for article (PubMed ID: 27297451)
1. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 6: Adrenal surgery.
Steichen O; Amar L; Chaffanjon P; Kraimps JL; Ménégaux F; Zinzindohoue F
Ann Endocrinol (Paris); 2016 Jul; 77(3):220-5. PubMed ID: 27297451
[TBL] [Abstract][Full Text] [Related]
2. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 7: Medical treatment of primary aldosteronism.
Pechère-Bertschi A; Herpin D; Lefebvre H
Ann Endocrinol (Paris); 2016 Jul; 77(3):226-34. PubMed ID: 27315759
[TBL] [Abstract][Full Text] [Related]
3. SFE/SFHTA/AFCE primary aldosteronism consensus: Introduction and handbook.
Amar L; Baguet JP; Bardet S; Chaffanjon P; Chamontin B; Douillard C; Durieux P; Girerd X; Gosse P; Hernigou A; Herpin D; Houillier P; Jeunemaitre X; Joffre F; Kraimps JL; Lefebvre H; Ménégaux F; Mounier-Véhier C; Nussberger J; Pagny JY; Pechère A; Plouin PF; Reznik Y; Steichen O; Tabarin A; Zennaro MC; Zinzindohoue F; Chabre O
Ann Endocrinol (Paris); 2016 Jul; 77(3):179-86. PubMed ID: 27315757
[TBL] [Abstract][Full Text] [Related]
4. Outcomes analysis of surgical and medical treatments for patients with primary aldosteronism.
Park KS; Kim JH; Yang YS; Hong AR; Lee DH; Moon MK; Choi SH; Shin CS; Kim SW; Kim SY
Endocr J; 2017 Jun; 64(6):623-632. PubMed ID: 28458337
[TBL] [Abstract][Full Text] [Related]
5. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 4: Subtype diagnosis.
Bardet S; Chamontin B; Douillard C; Pagny JY; Hernigou A; Joffre F; Plouin PF; Steichen O
Ann Endocrinol (Paris); 2016 Jul; 77(3):208-13. PubMed ID: 27036860
[TBL] [Abstract][Full Text] [Related]
6. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 1: Epidemiology of PA, who should be screened for sporadic PA?
Baguet JP; Steichen O; Mounier-Véhier C; Gosse P
Ann Endocrinol (Paris); 2016 Jul; 77(3):187-91. PubMed ID: 27087531
[TBL] [Abstract][Full Text] [Related]
7. Eplerenone improves carotid intima-media thickness (IMT) in patients with primary aldosteronism.
Matsuda Y; Kawate H; Matsuzaki C; Sakamoto R; Shibue K; Ohnaka K; Anzai K; Nomura M; Takayanagi R
Endocr J; 2016; 63(3):249-55. PubMed ID: 26727302
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of drug-based and surgical treatments for primary aldosteronism.
Steichen O; Lorthioir A; Zinzindohoue F; Plouin PF; Amar L
Adv Chronic Kidney Dis; 2015 May; 22(3):196-203. PubMed ID: 25908468
[TBL] [Abstract][Full Text] [Related]
9. Systematic review of surgery and outcomes in patients with primary aldosteronism.
Muth A; Ragnarsson O; Johannsson G; Wängberg B
Br J Surg; 2015 Mar; 102(4):307-17. PubMed ID: 25605481
[TBL] [Abstract][Full Text] [Related]
10. Adrenalectomy is comparable with medical treatment for reduction of left ventricular mass in primary aldosteronism: meta-analysis of long-term studies.
Marzano L; Colussi G; Sechi LA; Catena C
Am J Hypertens; 2015 Mar; 28(3):312-8. PubMed ID: 25336498
[TBL] [Abstract][Full Text] [Related]
11. Mineralocorticoid Receptor Antagonists and Clinical Outcomes in Primary Aldosteronism: As Good as Surgery?
Sechi LA; Colussi GL; Novello M; Uzzau A; Catena C
Horm Metab Res; 2015 Dec; 47(13):1000-6. PubMed ID: 26667803
[TBL] [Abstract][Full Text] [Related]
12. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy.
Riester A; Reincke M
Eur J Endocrinol; 2015 Jan; 172(1):R23-30. PubMed ID: 25163723
[TBL] [Abstract][Full Text] [Related]
13. Diagnosing and Managing Primary Aldosteronism in Hypertensive Patients: a Case-Based Approach.
Carey RM
Curr Cardiol Rep; 2016 Oct; 18(10):97. PubMed ID: 27566330
[TBL] [Abstract][Full Text] [Related]
14. Systematic review of the clinical outcomes of mineralocorticoid receptor antagonist treatment versus adrenalectomy in patients with primary aldosteronism.
Satoh M; Maruhashi T; Yoshida Y; Shibata H
Hypertens Res; 2019 Jun; 42(6):817-824. PubMed ID: 30948836
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Outcomes with Surgical and Medical Management of Primary Aldosteronism.
Wachtel H; Fraker DL
Curr Cardiol Rep; 2021 Jun; 23(7):89. PubMed ID: 34081226
[TBL] [Abstract][Full Text] [Related]
16. Unilateral primary aldosteronism with spontaneous remission after long-term spironolactone therapy.
Yoneda T; Demura M; Takata H; Kometani M; Karashima S; Yamagishi M; Takeda Y
J Clin Endocrinol Metab; 2012 Apr; 97(4):1109-13. PubMed ID: 22337911
[TBL] [Abstract][Full Text] [Related]
17. Mineralocorticoid receptor antagonists and renal involvement in primary aldosteronism: opening of a new era.
Catena C; Colussi G; Sechi LA
Eur J Endocrinol; 2013 Jan; 168(1):C1-5. PubMed ID: 23082005
[TBL] [Abstract][Full Text] [Related]
18. Renal Outcomes in Medically and Surgically Treated Primary Aldosteronism.
Hundemer GL; Curhan GC; Yozamp N; Wang M; Vaidya A
Hypertension; 2018 Sep; 72(3):658-666. PubMed ID: 29987110
[TBL] [Abstract][Full Text] [Related]
19. Long-term effect of specific treatment of primary aldosteronism on carotid intima-media thickness.
Holaj R; Rosa J; Zelinka T; Štrauch B; Petrák O; Indra T; Šomlóová Z; Michalský D; Novák K; Wichterle D; Widimský J
J Hypertens; 2015 Apr; 33(4):874-82; discussion 882. PubMed ID: 25490707
[TBL] [Abstract][Full Text] [Related]
20. Treatment of primary aldosteronism: Clinical practice guidelines of the Taiwan Society of Aldosteronism.
Tseng CS; Chan CK; Lee HY; Pan CT; Peng KY; Wang SM; Huang KH; Tsai YC; Wu VC; Chueh JS;
J Formos Med Assoc; 2024 Mar; 123 Suppl 2():S125-S134. PubMed ID: 37328332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
